LEO Pharma A/S, Ballerup, Denmark.
Lumanity, London, UK.
Contact Dermatitis. 2024 Apr;90(4):365-371. doi: 10.1111/cod.14477. Epub 2024 Jan 1.
Chronic Hand Eczema (CHE) is a heterogeneous fluctuating inflammatory disease that represents a significant burden. Effective treatment options for moderate to severe CHE are limited.
To assess how patients with moderate to severe CHE are treated in clinical practice.
A retrospective, physician-led patient record review assessed the demographic, clinical and treatment characteristics of patients aged ≥18 years with CHE across seven countries. Each participating physician was requested to review records for their three most recent patients with moderate to severe CHE treated with a topical or systemic therapy.
A total of 264 physicians, of whom 88.6% were dermatologists and 70.1% were predominantly or partly hospital-based, reviewed the records of 792 patients. Signs were present on hands only in 56.4% of patients and the mean time on current treatment was 16.7 months. Overall, 62.9% of patients received systemic therapy and almost one-quarter (23.4%) were treated with a biologic; 28.6% of patients were only treated with topical corticosteroids and/or topical calcineurin inhibitors.
In patients with moderate to severe CHE, most received systemic therapy with one-quarter on biologic therapy. However, given that many of these treatments have limited evidence of efficacy in CHE, there is a need for studies specifically in patients with CHE as well as new therapeutic options.
慢性手部湿疹(CHE)是一种异质性波动的炎症性疾病,给患者带来了沉重的负担。对于中重度 CHE,有效的治疗选择有限。
评估中重度 CHE 患者在临床实践中的治疗情况。
回顾性、医生主导的患者病历回顾评估了七个国家中年龄≥18 岁的中重度 CHE 患者的人口统计学、临床和治疗特征。每位参与的医生被要求回顾其最近治疗的三位中重度 CHE 患者的病历,这些患者接受了局部或全身治疗。
共有 264 名医生参与了回顾,其中 88.6%为皮肤科医生,70.1%主要或部分为医院医生。这些医生回顾了 792 名患者的病历。仅手部有症状的患者占 56.4%,目前治疗的平均时间为 16.7 个月。总体而言,62.9%的患者接受了全身治疗,近四分之一(23.4%)接受了生物制剂治疗;28.6%的患者仅接受了局部皮质类固醇和/或局部钙调神经磷酸酶抑制剂治疗。
在中重度 CHE 患者中,大多数患者接受了全身治疗,其中四分之一接受了生物制剂治疗。然而,鉴于这些治疗方法在 CHE 中的疗效证据有限,仍需要针对 CHE 患者进行专门的研究,并寻求新的治疗选择。